Sylogist Announces Release Date for Its Third Quarter 2026 Results 
Planet Ventures Announces Appointment of Charanjit Hayre as Incoming Chief Executive Officer & Issues Stock Options 
Stardust Solar Clarifies Recent Issuance of Convertible Debenture Units 
Access Panels Direct Launches Online Ordering for Made to Measure 2 Hour Fire Rated Riser Doors 
Reklaim Ltd. Announces Proposed Amendment to Convertible Debentures Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome
Quoin Will Initiate Clinical Testing in 1H 2022 ASHBURN, Va., April 25, 2022 (GLOBE NEWSWIRE)…
CB Therapeutics rapidly expands cellular agriculture capabilities at new facility
Chief Science Officer and CB Therapeutics co-founder, Dr. Jacob Vogan, working alongside Laboratory Manager, Diana…
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment…
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30…
Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical…
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
– Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)– AMT-101…
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a…
Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting
Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the…
Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR
Interim analysis provides response data from 7 evaluable patients including two additional patients, one with…
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for…
Vaccinex, Inc. Announces Upcoming Presentation at the PEGS Boston Conference & Expo Highlighting Its ActivMAb® Technology for Complex Membrane Antigen Expression to Enable Drug Discovery
ActivMAb technology to generate Complex Membrane Antigen Virus is a valuable drug discovery tool for…
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
Presentations showcase breadth of Vor Bio’s multiplex editing capability including base editing of human hematopoietic…
BioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference
CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
Xalud Therapeutics Adds Amy Chappell, M.D., as a Strategic Advisor
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) — Xalud Therapeutics, a clinical-stage biotechnology company developing…
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability…
Science 37 to Report First Quarter 2022 Financial Results on May 9, 2022
RESEARCH TRIANGLE PARK, N.C., April 25, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
Phase 1/2 study to assess the safety and efficacy of OCU400 modifier gene therapy candidate…
OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment
ROCKVILLE, Md., April 25, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine…
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO;…
PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine
Presentation evaluates the effect of D-PLEX100 in limiting occurrence of antimicrobial resistance (AMR) in colorectal…